It is currently Fri Apr 29, 2016 7:14 am

News News of Tysabri (Antegren or Natalizumab)

Site map of Tysabri (Antegren or Natalizumab) » Forum : Tysabri (Antegren or Natalizumab)

A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis

It's BACK!!!!!!!!

US OKs resumed sales of Biogen and Elan's Tysabri


WASHINGTON (Reuters) - Biogen Idec Inc. and Elan Corp. won permission on Monday to resume sales of their multiple sclerosis drug Tysabri, which was withdrawn last year after it was linked to a rare but potentially fatal brain disease, U.S. regulators said.


The U.S. Food and Drug Administration said Tysabri must be sold under a restricted distribution plan to minimize chances of harm. Tysabri should be ...
Read more : It's BACK!!!!!!!! | Views : 2130 | Replies : 6


Tysabri back soon

The Sunday Times says that Tysabri might get FDA approval this week.

Sorry to spoil you Sunday lunch HarryZ :lol: Perhaps you could turn your attention to Rituxan or Dacluzimab.

The article says that Tysabri will be $23,000 a year. About as much as Harry takes each month from the dividends from his Biogen shares. :lol:

Ian


...
Read more : Tysabri back soon | Views : 1593 | Replies : 1


Presentation

One for you HarryZ - UK MS Society presentation on Tysabri

Ian

http://www.mssociety.org.uk/document.rm?id=1405
Read more : Presentation | Views : 1906 | Replies : 3








Tysabri approved in EU

Just something i stumbled across this morning

The EU's CHMP has recommended approval of Elan and Biogen Idec's Tysabri (natalizumab), as a monotherapy for multiple sclerosis.

The product, which was launched in the US in late 2004 and voluntarily suspended two months later, has been given the go-ahead in the EU for use to delay the progression of disability and reduce the frequency of relapses in patients with high disease activity despite treatment with a ...
Read more : Tysabri approved in EU | Views : 1618 | Replies : 0


EU recommends restricted availability

Recommendations on Tysabri release restriction

28 April 2006 11:56

The European Medicines Agency (EMA) has recommended that the multiple sclerosis treatment drug, Tysabri, should be made available to patients on a restricted basis.

Tysabri was withdrawn from the market early in 2005 after some US patients who had been treated with the drug in combination with other medication developed the brain disease, PML.

The decision led to the collapse of Élan's share price.

Since then ...
Read more : EU recommends restricted availability | Views : 1527 | Replies : 1


Tysabri re-release

I lost my pipeline of informations regarding Tysabri, when my Dr. had by-pass surgery. I am looking ofr any information regarding its re-release. The news I got form my Dr.s RN was pretty discouraging.

Tracy Taggart
Read more : Tysabri re-release | Views : 1656 | Replies : 1


New Data on TYSABRI Demonstrate Significant Effects

6 April 2006

New Data on TYSABRI(R) Demonstrate Significant Effects on Health-Related Quality of Life Measures in Patients with Multiple Sclerosis

SAN DIEGO--(BUSINESS WIRE)--April 6, 2006--

Data presented at American Academy of Neurology Annual Meeting also Show Impact on Measures of Visual Function and Disability Progression

Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced today that in Phase III multiple sclerosis (MS) studies TYSABRI(R) (natalizumab) showed significant effects on pre-specified health-related quality ...
Read more : New Data on TYSABRI Demonstrate Significant Effects | Views : 2002 | Replies : 2


 

Login  •  Register


Statistics

Total posts 231995 • Total topics 24779 • Total members 15946


Contact us | Terms of Service